Related Experiment Video
Updated: May 17, 2025
10:02
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
1.8K
Triterpenoids with inhibitory effects on lipid accumulation from Ganoderma lucidum
Lu Chai1, Xiao-Cui Liu1, Zhou-Wei Wu1
1State Key Laboratory of Phytochemistry and Natural Medicines, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, Yunnan, People's Republic of China; University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China.
Fitoterapia
|May 5, 2025
Summary
This study isolated novel lanostane triterpenoids from Ganoderma lucidum, with some showing inhibitory effects on lipid accumulation in liver cells. Structure-activity analysis highlights potential for developing new anti-obesity compounds.
Area of Science:
- Natural Product Chemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Ganoderma lucidum is a medicinal mushroom with a rich history of use.
- Triterpenoids are a diverse class of natural products with various biological activities.
- Understanding the chemical constituents and bioactivities of G. lucidum is crucial for its therapeutic applications.
Purpose of the Study:
- To isolate and characterize novel lanostane-type triterpenoids from cultivated Ganoderma lucidum.
- To evaluate the inhibitory effects of isolated compounds on lipid accumulation in oleic acid-induced HepG2 cells.
- To investigate the structure-activity relationships of these triterpenoids concerning their lipid-lowering potential.
Main Methods:
- Isolation of compounds from Ganoderma lucidum fruiting bodies using chromatographic techniques.
- Structure elucidation of isolated compounds via comprehensive spectroscopic methods (NMR, MS, etc.).
- In vitro evaluation of lipid accumulation inhibition in HepG2 cells stimulated with oleic acid (OA).
Main Results:
- Eight new lanostane-type triterpenoids (1-8) and 27 known analogues (9-35) were identified.
- Ganosinenic acids D (1) and E (2) possess a rare pentacyclic triterpenoid structure with a four-membered ring.
- Compounds 7, 9, and 29 demonstrated moderate inhibition of lipid accumulation; compound 9 exhibited dose-dependent inhibition.
- Degraded C27 nor-triterpenoids showed enhanced efficacy compared to C24 and C30 analogs.
Conclusions:
- Cultivated Ganoderma lucidum is a valuable source of structurally diverse lanostane triterpenoids.
- Specific triterpenoids from G. lucidum exhibit potential for modulating lipid metabolism.
- Structural modifications, particularly side-chain degradation, can enhance the anti-lipid accumulation activity of these compounds.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
475
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
475
01:30Enzyme Inhibition
77.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.5K
01:23Dipeptidyl Peptidase 4 Inhibitors
140
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
488
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
488
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
128
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
128
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K